Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Published: April 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
Published: April 01, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Hims & Hers Expands Personalized Digital Healthcare Platform
Published: March 31, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS builds a digital-first healthcare platform, integrating telehealth, AI and personalized treatments while expanding globally and into new specialties.
Read More
Hims & Hers: The Reset Before The Next Inflection
Published: March 27, 2026 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health shares rallied to ~$27 after the early-March Novo deal before resetting to ~$20, still leaving the stock ~40% above prior coverage levels. Short interest remains elevated at ~83.3M shares (~40% float), while days-to-cover expanded from ~1.0 to ~3.6. Short volume intensity declined from ~62–64% during the selloff to ~45%, signaling reduced marginal short pressure.
Read More
Hims & Hers: Distressed Valuations Will Not Last For Long
Published: March 25, 2026 by: Seeking Alpha
Sentiment: Negative
Hims resolved its legal dispute with Novo Nordisk, removing a major overhang and enabling it to offer branded drugs. Valuations have not recovered to pre-lawsuit levels as persistent insider selling and changes in disclosure have weighed negatively on sentiment. Consensus underestimates the inherent story in Hims emanating from growth in subscribers, sustainability and penetration in new products & markets.
Read More
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?
Published: March 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
Read More
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
Published: March 25, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
Published: March 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
Read More
INSP vs. HIMS: Which Stock Should Value Investors Buy Now?
Published: March 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical Info Systems stocks are likely familiar with Inspire Medical Systems (INSP) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Hims & Hers Expands Integrated Digital Healthcare Ecosystem
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS builds a seamless digital healthcare ecosystem, expanding into diagnostics, global markets and specialty care to reshape access and delivery.
Read More
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal
Published: March 09, 2026 by: Invezz
Sentiment: Positive
Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers.
Read More
Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal
Published: March 09, 2026 by: Invezz
Sentiment: Positive
Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers.
Read More
YieldMax® HIMS Option Income Strategy ETF (HIYY) Trading Halt
Published: March 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
MILWAUKEE, March 05, 2026 (GLOBE NEWSWIRE) -- Tidal Investments LLC (“Tidal”) announces that the YieldMax® HIMS Option Income Strategy ETF (NYSE Arca: HIYY) was halted to allow Tidal to evaluate the accuracy of the HIYY Net Asset Values per share (NAVs) published for March 2, 3, and 4, 2026. Tidal determined the NAV for HIYY was required to be restated on March 2 from $12.38 per share to $12.15 per share, on March 3 from $9.92 per share to $11.81 per share and on March 4 from $10.24 per share to $12.13 per share.
Read More
Hims and Hers Expands Its Technology Driven Consumer Health Platform
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its tech-driven care platform with data-led Labs testing, new menopause and testosterone services and global expansion into Canada.
Read More
Hims & Hers Health: Leaving GLP-1s Behind
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers (HIMS) remains a 'Strong Buy' at $16, with fair value estimated at $22 despite recent headwinds. International expansion via the $1.15B Eucalyptus acquisition and product diversification are key drivers, though margins will remain pressured. GLP-1 regulatory risks have intensified, but HIMS is pivoting to diversified growth pillars beyond weight loss.
Read More
Hims' pharmacy partner will reintroduce GLP-1 pill pulled from market, Endpoints News reports
Published: March 03, 2026 by: Reuters
Sentiment: Neutral
Hims & Hers Health's pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded weight‑loss pill through other healthcare providers after halting distribution following U.S. regulatory pushback, Endpoints News reported on Tuesday.
Read More
Carillon Eagle Small Cap Growth Fund Q4 2025 Portfolio Review
Published: March 02, 2026 by: Seeking Alpha
Sentiment: Positive
Coherent is expected to continue to benefit from a transition to products that enable faster throughput speeds, while prior constraints on manufacturing capacity appear to be alleviating. BrightSpring Health Services reported another strong quarter with both revenues and EBITDA up significantly, far outpacing its historical growth rate prior to going public in 2024. Varonis Systems, which provides data protection security software, delivered disappointing earnings results and an outlook below expectations.
Read More
Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
Published: March 02, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CLICK HERE TO PARTICIPATE. What Happened? On February 7, 2026, The New York Times re.
Read More
Hims expansion may not come in time for risky GLP-1 business
Published: March 02, 2026 by: Reuters
Sentiment: Negative
Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soon enough for investors who are growing impatient.
Read More
Hims & Hers Expands Digital Health and Global Platform Strategy
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS expands into labs, cancer screening, menopause and global markets, advancing its digital, subscription-driven healthcare platform and preventive care.
Read More
Law Offices of Howard G. Smith Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
Published: February 27, 2026 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howard.
Read More
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making
Published: February 27, 2026 by: The Motley Fool
Sentiment: Positive
Hims & Hers offers direct-to-consumer healthcare in a digitally native manner. The company is profitable, and its subscriber base is growing.
Read More
HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Let's dive in.
Read More
Hims & Hers Health: The GLP-1 Party Is Over
Published: February 25, 2026 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health, Inc. is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. HIMS' reliance on compounded GLP-1 drugs has faltered, with regulatory headwinds and an SEC investigation clouding visibility and investor trust. Despite solid subscriber and revenue growth, margin compression and weak guidance highlight unsustainable marketing intensity and operational risks.
Read More
Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading
Published: February 24, 2026 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health, Inc. faces severe volatility, regulatory scrutiny, and legal risks, especially in its weight-loss drug segment, yet I maintain a cautious BUY rating. Q4 results showed revenue of $617.8M (+28% YoY) and adjusted EBITDA of $66.3M, but subscriber growth and Q1 guidance disappointed due to GLP-1 headwinds. International expansion and labs initiatives are key growth drivers, with management targeting $1B+ annual international revenue and $1.3B adjusted EBITDA by 2030.
Read More
Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Negative
HIMS reports an earnings beat and strong revenue growth in fourth-quarter 2025, but margin pressure and a softer outlook clouded the quarterly performance.
Read More
KDP Beats & HIMS Misses Sales, QCOM Gains on Upgrades
Published: February 24, 2026 by: Schwab Network
Sentiment: Neutral
Keurig Dr. Pepper (KDP) didn't fizzle out when it came to earnings, with Diane King Hall noting a beat Tuesday morning. Hims & Hers (HIMS) couldn't do the same as the telehealth company sees headwinds as subscribers shrink.
Read More
Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard
Published: February 24, 2026 by: 24/7 Wall Street
Sentiment: Negative
Shares of Hims & Hers Health ( NYSE:HIMS ) are trading lower this morning after yesterday's earnings, and the reason is straightforward: guidance.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Medical - Equipment & Services
- CEO Andrew Dudum
- Employees 1637